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Abstract
Background: The objective of this study was to enhance removal of fishing gear from right whales (Eubalaena glacialis) at
sea that evade disentanglement boat approaches. Titrated intra muscular injections to achieve sedation were undertaken
on two free swimming right whales.
Methodology/Principal Findings: Following initial trials with beached whales, a sedation protocol was developed for right
whales. Mass was estimated from sighting and necropsy data from comparable right whales. Midazolam (0.01 to 0.025 mg/
kg) was first given alone or with meperidine (0.17 to 0.25 mg/kg) either once or four times over two hours to whale #1102
by cantilevered pole syringe. In the last attempt on whale #1102 there appeared to be a mild effect in 20–30 minutes, with
duration of less than 2 hours that included exhalation before the blowhole fully cleared the water. Boat avoidance, used as a
measure of sedation depth, was not reduced. A second severely entangled animal in 2009, whale #3311, received
midazolam (0.03 mg/kg) followed by butorphanol (0.03 mg/kg) an hour later, delivered ballistically. Two months later it was
then given midazolam (0.07 mg/kg) and butorphanol (0.07 mg/kg) simultaneously. The next day both drugs at 0.1 mg/kg
were given as a mixture in two darts 10 minutes apart. The first attempt on whale #3311 showed increased swimming
speed and boat avoidance was observed after a further 20 minutes. The second attempt on whale #3311 showed
respiration increasing mildly in frequency and decreasing in strength. The third attempt on whale #3311 gave a statistically
significant increase in respiratory frequency an hour after injection, with increased swimming speed and marked reduction
of boat evasion that enabled decisive cuts to entangling gear.
Conclusions/Significance: We conclude that butorphanol and midazolam delivered ballistically in appropriate dosages and
combinations may have merit in future refractory free swimming entangled right whale cases until other entanglement
solutions are developed.
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Introduction
Human impacts on North Atlantic right whales (Eubalaena
glacialis) have largely erased potential population growth despite
robust recent calving rates [1]. The major traumas found at
necropsy have been propeller cuts and blunt trauma from vessels,
and constrictive trauma from fishing gear entanglement [2]. Since
first pioneered by Jon Lien in Canada in the 1970’s [3], whale
disentanglement techniques have been attempted mostly on
animals anchored by fishing gear. Newer techniques developed
in the 1980’s by the Provincetown Center for Coastal Studies,
Provincetown, MA, USA, (PCCS) are now being used to
disentangle free-swimming entangled whales. These techniques
rely primarily on physical restraint by adding buoyancy and drag
to the trailing gear. Using small boats, buoys and drogues in an
effort to tire and restrict movement of the whale, entangling gear
can be removed with relative safety using pole-mounted knives.
Disentanglement success rates have varied by species and
entanglement configuration, with some species being more
tractable than others: critically endangered right whales being
the least tractable. Free-swimming right whale entanglement cases
exhibiting wraps of line far forward on the body, in areas such as
the rostrum and flippers, have the lowest disentanglement success
rate to date (PCCS unpublished data). The primary position for
attempting to cut line in a free swimming whale has been from
behind the tail within a boat towed by the whale, as this is a
position of relatively higher human safety. However this position
often greatly limits access to entangling lines. In 1999 an entangled
right whale catalogued by the New England Aquarium as #2030
(http://rwcatalog.neaq.org) proved to be refractory to multiple
disentanglement attempts. It was first sighted entangled on May 10
1999 with fishing gear stretched taught between both axillae that
had stripped off large pieces of dorsal blubber and skin. The
disentanglement team requested assistance to deliver antibiotics to
the whale once it had been disentangled. A pole syringe based on a
cantilevered pole system [4] was prepared and attempts to
physically restrain the animal using a tail harness were made by
PCCS and others. The animal was never disentangled, and drugs
were not delivered. The whale eventually died 5 months later.
Animal welfare and conservation concerns in this case initiated the
question of planning for medical intervention in similar cases. The
possibility of sedating animals to enhance disentanglement was
discussed. There is a history of the use of sedatives in captive
marine mammals [5] where benzodiazepines or meperidine have
enabled stressful procedures such as gastroscopy and bronchosco-
py [6,7]. Despite earlier predictions of the dire consequences of
using immobilizing drugs in free swimming animals [8], an initial
attempt to deliver sedatives to a right whale has been briefly
reported [9]. Here we describe the details of that attempt, as well
as a subsequent right whale sedation and disentanglement.
Methods
Delivery Systems
A pole syringe was developed for use on right whale #1102
because existing ballistic drug delivery systems for terrestrial
species had inadequate volume for such large animals. A
cantilevered pole system, originally designed for measuring
blubber thickness acoustically [4] was adapted to be practical in
a small inflatable boat, with an open pivot to allow immediate
release from the boat if need be. A polycarbonate syringe was
fabricated with a check valve, plunger and a stainless steel needle
(Figure 1). The pressure chamber was filled with butane to a
pressure at which the butane condensed to a liquid. The side
injection port on the distal portion of the needle carried a tygon
tube sleeve that was displaced upon entry into the animal allowing
the butane under pressure to advance the plunger and inject the
drug. A carcass trial was conducted to establish the weight and
elevation of needle holder required to ensure efficient muscle
penetration.
Simpler systems, such as a hand held pole, a crossbow, and a
spear gun were tested and rejected on grounds of safety.
A ballistic syringe (Paxarms, 37 Kowhai St, Timaru, New
Zealand), was developed for use on right whale #3311. The dart
portion of this system operates on the same principle as the syringe
illustrated in Figure 1. The syringe body comprised a 33 cm long
by 19 mm diameter anodized aluminum tube threaded at both
ends, machined to have an O ring seat. The flight end cap has a
valve to allow pressurization of air behind the plunger. The 30 cm
long66.4 mm outside diameter stainless steel needle is lined with a
carbon fiber tube and has 3 end ports. A rubber stop screws over
the end piece. All O rings as well as the syringe and projector
barrel are coated with silicon lubricant. The projector is a
modified.22 caliber rifle, firing blanks custom filled by Paxarms.
An adjustment of a valve controlling air flow in to the expansion
chamber allows for compensation of the firing power dependent
on range of firing. This adjustment is linked to the sighting scope
such that the sight compensates for the required trajectory. A
stainless steel leader is attached via a swivel to the rear of the
syringe. The leader runs up corresponding grooves in the syringe
and projector barrel to be tied to 20 m of 80 kg test line wound
around the projector barrel tip, and then tied to a 22.86 cm (9in)
Figure 1. Schematic of polycarbonate pole syringe for injecting a large whale at sea (dimensions in inches (mm). The Paxarms ballistic
syringe operates on a similar principle.
doi:10.1371/journal.pone.0009597.g001
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long by 7.62 cm (3in) wide cm styrofoam ‘Shark’ float. The line
windings on the barrel are lightly wrapped with office sticky tape
to allow it to peel off once the dart is fired. The dart is fired at a
range of about 15 m. The line spins off the barrel and the float is
left to trail behind the whale until the drag on the float extracts the
needle.
Sedatives
Midazolam (a benzodiazepine anxiolytic, amnestic, hypnotic,
anticonvulsant and muscle relaxant) in ethanol was compounded
for the initial trials on whale #1102 by University of Wisconsin
Veterinary School Pharmacy (2015 Linden Drive, Madison, WI,
USA). Use of the commercial drug at 5 mg/ml was impractical, so
the midazolam base was concentrated in ethanol to reduce the
total volume administered. Meperidine (an opioid analgesic) was
supplied by University of Wisconsin Veterinary School Pharmacy.
The normal commercial grade drug is available at 100 mg/ml.
For this attempt it was concentrated to 550 mg/ml. An aqueous
solution of midazolam HCl was also used, compounded by
ZooPharm (Box 2023, Fort Collins, CO, USA). Butorphanol (an
opioid analgesic) was supplied by ZooPharm and could be mixed
with midazolam HCl. Concentrations used are given in Table 1.
Reversal
Naltrexone (ZooPharm 50 mg/ml) has been used to reverse the
sedative effects of butorphanol in other cetaceans [10,11] at
0.005 mg/kg to 0.3 mg/kg i/m (intra-muscular) and was available
in the event of problems with the sedation.
Ethics
This research was undertaken after approval and permitting by
the National Oceanic Atmospheric Administration Office of
Protected Resources under the Marine Mammal Protection Act
and Endangered Species Act. Enhancing the welfare of the
subject, severely entangled animals, was the primary agenda of the
research and in the case of whale #3311 (Figure 2), welfare was
perhaps significantly improved by the procedure described.
Strategy
Given the many unknowns in terms of doses and effects it was
agreed that the only animals that would be considered for sedation
were those that would likely die, if not disentangled, and could not
be not disentangled by more traditional means; and that could be
telemetry-tracked prior to sedation attempts, for visual health
assessments and planning. The vessel used for sedation of whale
#3311 was a 7.2 m rigid hull inflatable boat (RHIB) operating one
of two 90 hp four cycle outboard motors, with the projection
system being operated from a platform 2.5 m above sea level. The
disentanglement vessel approaching whale #3311 was a 5.5 m
RHIB with a 90 hp 4 cycle outboard motor. Whale weights were
estimated on the basis of available necropsy and catalog data
[2].
Experimental Design
Delivery system and drug trials were undertaken sequentially on
whales that were beached, trapped in a river and at sea. Drug use
and delivery protocols were iteratively developed through a series
of 5 consecutive trials, evolving the treatment regimen in light of
accrued findings.
Results
Trial 1
An emaciated juvenile gray whale (Eschrichtius robustus) beached
in ventral recumbency along the California coast on April 8th
2000. It was824 cm in length, 264 cm in axillary girth,with a
ventral axilla blubber depth of 75 mm, and with an intact blink
reflex. It was hand injected with 25 cc of 51 mg/ml midazolam i/
m into the lateral periaxial lumbar area mid body using a 7.6 cm
18 G spinal needle. Twelve minutes later, the blink reflex was
diminished, 29 minutes after injection the peduncle could be lifted
with no response and a blood sample taken. The animal was
euthanased 38 minutes after injection. The estimated weight of
this animal was of the order of 5000 kg [12]. Thus the dose given
was of the order of 0.025 mg/kg.
Table 1. Summary of Sedation Dosing of Two Right Whales.
Date Time Drug
Concen-tration
(mg/ml)
Assumed
weight (kg)
Dose
mg/kg Result
Right Whale # 1102 (Year 2001)
Jun 26th Midazolam 90 45000 0.01 No effect
Jul 14th Midazolam 90 45000 0.025 No effect
Meperidine 550 0.017
Aug 30th Over 2 h. Midazolam 90 40000 0.1 Less forceful surfacings, and exhaling before the blowhole
was clear of the water with a less powerful blow.
Meperidine 550 1
Right Whale # 3311 (Year 2009)
Jan 23rd 1433 Midazolam 70 20000 0.028 Increased speed and avoidance 20 minutes later
1533 Butorphanol 50 0.033
Mar 5th 1418 Midazolam 50 20000 0.071 Oblique?did not penetrate subdermal sheath. Respiration
increased frequency, decreased depth. Not statistically
signficant. No reduction in boat aversion
1418 Butorphanol 50 0.071
Mar 6th 1133 to
1143
Midazolam 50 20000 0.1 Marked reduction of boat avoidance. Respiration increased
frequency, decreased depth.
1143 Butorphanol 50 0.1
doi:10.1371/journal.pone.0009597.t001
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Trial 2
Right whale #1102 was observed by an aerial survey on June 8,
2001 to have a severe head entanglement, with associated deep
incision across the rostrum. A telemetry buoy was attached to the
trailing gear by PCCS on June 9th. The animal proceeded to move
extensively in the Gulfs of Maine and St Lawrence. The first major
disentanglement effort was in the Great South Channel southeast of
Nantucket, MA, USA, June 26th, 2001, at which time the condition
of the animal had significantly deteriorated. The whale was assumed
to weigh 45,000 kg. Midazolam and meperidine were chosen for
these initial attempts based on successful use of midazolam alone or
in combination with meperidine in other cetaceans (Walsh, personal
communication, clinical records and [6]). Balancing the potential
difference in metabolism from previous use in other species it was
decided to start with lower relative dosages and one drug. The dose
of midazolam administered was 0.01 mg/kg and again 37 minutes
later using the cantilevered pole syringe [4]. There was no evident
effect on the animal. Meperidine (an opioid analgesic) was then
added at the second disentanglement attempt on July 14th.
Midazolam was given at 0.025 mg/kg. The meperidine dose given
was 0.17 mg/kg. There was no evident effect on the animal. On
August 30th a third attempt was made assuming a 40,0001kg whale
using a) midazolam at 0.025 mg/kg, at a concentration of 90 mg/
ml, giving an 11 ml/dose and b) meperidine at 0.251mg/kg, at a
concentration of 550 mg/ml giving an 18 ml dose. The above
combined dose was given four times in 2 hours. There appeared to
be an onset of effect in 20–30 minutes with duration of effect of less
than 2 hours. The level of central nervous system depression
appeared to be low. The animal did however appear to some, but
not others, to be mildly sedated, exhibiting less forceful surfacings,
and exhaling before the blowhole was clear of the water with a less
powerful blow. The animal was however not disentangled on any of
these attempts. Dosing information for this and a subsequent case
are given in Table 1. The last satellite transmission was on Sept. 16th
2001, presumably when the whale and telemetry buoy sank.
Trial 3
After land and carcass based trials demonstrated the apparent
utility of the Paxarms system, it was used to successfully deliver
antibiotics to two free swimming humpback whales (Megaptera
novaeangliae) in the Sacramento River, CA USA on May 26th 2007
[13]. It deployed well, and the darts detached from the animals
within 2 to 24 hours.
Trial 4
The Paxarms system was also used to administer 50 ml of
600 mg/ml meperidine as a pre euthanasia drug to a moribund
beached sperm whale (Physeter macrocephalus) at Terra Ceia,
Manatee, FL, USA on January 1st 2008. The system performed
well though the level of sedation achieved was not easy to ascertain
as a result of the depressed condition of the animal.
Trial 5
The Paxarms system was first deployed for a series of sedation
attempts on a chronically entangled right whale #3311, an animal
of unknown sex, born in 2003 (Figure 2). After being observed gear
free on April 21st 2008, the animal was first reported entangled on
January 14th 2009 18 miles off Brunswick GA, USA. After being
assessed with a fatal entanglement and serious injuries at the
rostrum and lower lip, a telemetry tag was attached to the trailing
entangling gear that afternoon. Body mass was estimated at
20,000 kg from a published age/mass curve [2]. On January 23rd
2009, 15 nm east of St Augustine Inlet midazolam in ethanol was
given at 0.028 mg/kg and butorphanol hydrochloric acid (HCl) at
0.033 mg/kg (Table 1). Increased speed and avoidance was noted
20 minutes later. Conditions precluded a further dosing attempt.
The two drugs were immiscible given their ethanol vs. water base,
thus this combination was less desirable for future administration
where volume would be a limiting factor.
March 5th 2009 – Right whale #3311 was sighted 15.6 nm NE
of Ponce de Leon Inlet, FL, USA. Respirations were recorded
starting at 14:09. A dart loaded with 0.071 mg/kg midazolam HCl
and butorphanol HCl was delivered at 14:18. Respirations per five
minutes increased from 3 to 5 before darting to 5 to 7 after
darting – a notable but statistically insignificant change. At the
same time respiration depth appeared to decrease. At times
exhalation began before the blowhole was clear of the water.
There was no reduction in the evasiveness of the animal to boat
Figure 2. Image of rope cutting in to the head of right whale #3311. This whale trailed line that cut into the upper jaw. The curved organ
below the line is the left lip. The double slotted blowhole is evident at right. The brown color covering the skin is a mass of cyamid whale lice typical
of a right whale in very poor condition. Photograph credit – Florida Wildlife Research Institute.
doi:10.1371/journal.pone.0009597.g002
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approaches and no cuts to disentangle could be made. The angle
of insertion of the dart was shallow. Thus it was unclear if all or
some of the drug was injected into the blubber rather than the
muscle, potentially delaying and or reducing the effect of the
drugs. But it was also felt that the breath pattern changes suggested
that the dose given had some effect and that the dose given was not
far from a useful effect. It was therefore agreed, at the next
opportunity, to increase the dose to near the top end of the clinical
range used in captive marine mammals: 0.1 mg/kg for both
midazolam and butorphanol, with a potential supplemental dose
of 0.025 mg/kg of both drugs if indicated.
On March 6th 2009 21.8 nm N of Cape Canaveral, FL, USA.
the plane relocated the whale at 10:34. Two darts were implanted
delivering 0.1 mg/kg midazolam HCl and 0.1 mg/kg butorpha-
nol (Table 1). Dart 1 was delivered at 11:33 low on the right flank
with full almost perpendicular penetration. The second dart was
delivered at 11:43 about 301cm ventral and cranial to the first
dart. The buoy for dart 1 trailed behind the whale’s flukes and
remained there until about 12:35 when the cutting boat observed
the dart buoy receding from the whale. It was recovered along
with the dart. The dart sleeve had been fully compressed in to the
rubber stopper showing full penetration, but with the syringe body
lying caudally, suggesting a bend in the needle at the skin surface
comparable to observations of darts deployed in other cases [13].
Subsequent examination showed about 5 ml of a watery dark red
liquid in the dart barrel. Cytology from a smear showed peracute
hemorrhage, with an abundance of eosinophilic, globular material
consistent with the drugs delivered.
At 12:06 the plane reported that before injection the whale had
been travelling at 1.5 knots and avoiding the sedation vessel
(Figure 3), and after injection the speed increased to 2 knots. It
travelled 0.63 nm in 18 minutes. The plan to assess the degree of
sedation was to make a boat approach and observe the persistence
of the characteristic strong boat avoidance reaction that was
ubiquitous in previous approaches to the animal. At 12:30 an
approach was made. By 12:43 three cutting approaches had been
made, the first of which did not allow for the spring loaded cutting
knife to make contact with the whale. Contact was made on three
subsequent approaches. The first and second cuts were a miss but
a cut to the head wrap was made at the third cutting attempt
(Figure 4). It was the opinion of the cutting boat crew (CS (driver)
and JS (cutter) that the behavior of the whale was markedly
different.
Breath counts in each five minute period were compared before
and after sedative injection on March 5th and 6th 2009 for whale
#3311. A Mann-Whitney rank sum test showed a significant
increase in respiratory frequency following drug delivery on
March 6th, but not March 5th (Figure 5 and Table 2). After being
freed of the majority of the line and the tracking buoy, the whale
began to move away from the disentanglement area. The plane
that was responsible for maintaining contact with the whale was
running low on fuel, and daylight, and was required to leave the
Figure 3. Right whale#3311 swimming at 11:30 on March 6th 2009 prior to sedation. The whale is in the bottom left of the image, and is
towing a line with buoys shown to the middle right. Note the sharp turn shown by the line, away from the boat attempting to approach the whale at
top left. Photograph credit Georgia Dept Natural Resources/Wildlife Trust.
doi:10.1371/journal.pone.0009597.g003
Right Whale Sedation
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9597
scene. The darting boat made one more parallel pass to take a set
of photos of the rope damage and to observe the animal’s
behavior.
The most notable change in behavior, post-sedation on March
6th 2009, was the whale’s apparent inability or desire to move
away from the approaching vessel. During previous events, and to
a lesser degree on March 5th 2009, the whale was able to cease an
intended surfacing 4–5 meters below the surface, lower its head
and lift its flukes to make the sharp left turn for avoidance
measures. Post-sedation on March 6th 2009, the whale seemed
indifferent to interrupting a surfacing for a second breath once it
had begun to make this surfacing. This made placement of the
boat next to the whale’s head and planning for the materials
needed for cutting much more achievable. Timing of surfacing was
essential for managing these short periods of interaction which
were directed with the help of the aircraft crew above. It was
noting this repetition of a second breath that enabled the
disentanglement team to make cuts. Shallowness of breath was
also mentioned by the sedation team as one of the observed effects
after darting. The whale remained under observation for 2 hours.
Once freed from the line and telemetry buoy the whale’s
swimming speed increased and respirations became deeper. It
was elected not to reverse the butorphanol at this point.
Discussion
Anesthesia, the act of reducing consciousness to a point where
surgery can be undertaken, is rarely attempted in cetaceans as it is
fraught with risk, given our very limited knowledge of cetacean
pharmacokinetics and the complexity of managing their breath
hold dive reflex, bradycardia, and high tolerance to acidosis [5]. In
contrast, sedation has been used more widely in captive and
beached cetaceans to facilitate procedures, since it reduces the
subject’s resistance without the risks associated with loss of
consciousness. Sedating large whales at sea in our study required
enhanced tractability, without any loss of ability to swim and
respire. The major risk of excessive sedation while still swimming
and diving was uncontrolled inhalation of water. Since there had
been no previous attempt to intervene medically with free ranging
cetaceans at sea, we had to develop drug delivery and use
protocols that achieved a sedated free swimming cetacean with
reduced resistance to being handled, while still swimming and
respiring voluntarily with no loss of equilibrium or inhalation of
water.
The initial choice of a cantilevered pole syringe was based on
the assumption that an adequately large syringe and needle length
could not be designed and built to be sufficiently accurate as a
Figure 4. Right whale#3311 swimming at 12:42 on March 6th 2009 after sedation. Whale is shown an hour after sedative administration
showing a marked reduction in boat avoidance as compared to the behavior shown in Figure 3. Photograph credit Georgia Dept Natural Resources/
Wildlife Trust.
doi:10.1371/journal.pone.0009597.g004
Right Whale Sedation
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9597
Figure 5. Number of breaths made by right whale #3311 in preceding five minutes, compared before and after sedation.
doi:10.1371/journal.pone.0009597.g005
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ballistic device. The pole syringe proved to be functional, but the
risk of being mechanically attached to the whale if the syringe did
not release from the pole, and the logistic complications of
deploying a cantilever system offshore, lead to a desire to revisit
the drug delivery system design and subsequent development of
the ballistic system built by Paxarms. One of the issues in the early
trials of this system was the inertia of the loaded syringe barrel
bending the implanted needle. Addition of a carbon fiber needle
liner solved this problem.
Concern about loaded darts that missed their target and
retained concentrated drug to be encountered by a third party,
lead to development of a tethered dart.
The choice of drugs was central to project development. Marine
mammal clinicians, with experience in sedating smaller cetaceans,
and veterinary anesthesiologists weighed cost against likely
efficacy. First priority was to utilize drugs that would result in
the most likely chance of success during disentanglement. At the
outset butorphanol was regarded as prohibitively costly. However,
given that it facilitated disentanglement in under two hours, its
costs may be offset by reductions in the number of days at sea
required for successful disentanglement.
The actual dose will always depend on an approximate estimate
of mass in the field, even though an intended mg/kg of drug is
prescribed. Most right whale cases will involve catalogued
individuals, so their age will often be known. Thus available
mass, length and age relationships from stranded animals [2] are
the best current option for mass estimation.
The reduction in boat aversion in whale #3311 on March 6th
2009 may have occurred as early as 30 minutes after the second dart
was injected, but it took an hour to close the distance to the whale and
prepare the cutting tools for cutting approaches. Care must be taken
to remain within striking distance of a sedated whale while remaining
far enough away to ensure that boat noise is not ‘‘pushing’’ the whale,
thus reducing the effects of sedation. This was especially true in the
case of whale #3311. The closing time for the 5.5 m RHIB was
much increased due to deteriorating sea conditions. In summary the
whale continued to breathe and dive, but was no longer avoiding boat
approaches as effectively as it was prior to sedation.
Comparing the behavior of whale #3311 during approaches
made on the third disentanglement event, spanning March 5th and
6th 2009, with behavior observed on January 22nd and 23rd 2009
and on February 1st 2009, it should be noted that the reduced
physical condition of the whale may have contributed to slower
movement in the water during close approaches and decreased the
time the whale could remain submerged under ‘‘close approach
stress’’ after a single breath surfacing. Sedation may also reduce
the depth of inhalation and deep diving avoidance behavior
resulting in more time near the surface and higher respiratory
rates. Increased respiration rates have been seen in other cetaceans
which spend more time near the surface. However prior to the
final sedation attempt this only marginally reduced the whale’s
ability to avoid the very close approaches needed for cutting. The
initial desire to stop the animal for extended work was not realistic
based on behavioral responses from captive individuals given
similar dosages. In this regard, a majority of sedated captive
dolphins, beluga, Pseudorca or Orca have maintained their capability
for movement and respirations. Variation in response may reflect
individual response to the drugs, drug dosage and the size of the
sedation pools used for administration and observation during
onset period of the sedatives. However there have been
observations of a decrease in resistance to handling and
manipulation, and subtle changes in respiratory quality and rate.
Reversal of midazolam with flumazenil was not practical since
this agent is not available in a concentrated form and would have
taken 400 mls minimum, equal to 7 additional darts. Flumazenil
also has a short half life, making the risk of re-induction real. The
evaluation of a whale’s need for reversal with these sedatives is
largely based on the behavioral response, though there may be
concern for the change in drug effects due to reduced stress levels
following disentanglement. Some animals may be overly sedated
after the completion of a procedure. It may be prudent, when
possible, to partially reverse the combined sedative effect by use of
naltrexone at the completion of the procedure since follow up is
often difficult without satellite tracking. Another option is to
decrease the midazolam dose to 0.075 mg/kg while maintaining
the butorphanol dose at 0.1 mg/kg until more individuals have
been studied. As of February 19th 2010 whale #3311 has not been
re-sighted dead or alive. Thus the success of the disentanglement
remains unknown. While use of the sedative system did enhance
disentanglement effectiveness in this case the enhancement to
survival remains unknown at this time. This was a conservative
sedative approach. There are more powerful sedative agents
available that could have potentially slowed the animal but these
have not been successfully used in other cetaceans and would be
more likely to lead to a negative animal outcome. The choice of
two reversible drugs used successfully in other cetacean species
minimized the risk to the animal, but the true impact of this new
technique cannot be assessed until it has been applied to a number
of other large whales.
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